anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The Angiotensin II for the Treatment of High-Output Shock (ATHOS-3) trial was a double-blind study in which 321 adults with septic or other distributive shock who remained hypotensive despite fluid and vasopressor therapy were randomized 1:1 and treated with either GIAPREZA or placebo, both in addition to background vasopressor therapy. Doses of GIAPREZA or placebo were titrated to a target MAP of ≥ 75 mmHg during the first 3 hours of treatment while doses of other vasopressors were maintained. From Hour 3 to Hour 48, GIAPREZA or placebo were titrated to maintain MAP between 65 and 70 mmHg while reducing doses of other vasopressors. The primary endpoint was the percentage of subjects who achieved either a MAP ≥ 75 mmHg or a ≥ 10 mmHg increase in MAP without an increase in baseline vasopressor therapy at 3 hours.

91% of subjects had septic shock; the remaining subjects had other forms of distributive shock such as neurogenic shock. At the time of study drug administration, 97% of subjects were receiving norepinephrine, 67% vasopressin, 15% phenylephrine, 13% epinephrine, and 2% dopamine. 83% of subjects had received two or more vasopressors and 47% three or more vasopressors prior to study drug administration. 61% of subjects were male, 80% were White, 10% were Black, and 10% were other races. The median age of subjects was 64 years (range: 22-89 years). Patients requiring high doses of steroids, patients with a history of asthma or bronchospasm, and patients with Raynaud's syndrome were not included.

The primary endpoint was achieved by 70% of patients randomized to GIAPREZA compared to 23% of placebo patients; p < 0.0001 (a treatment effect of 47%). Figure 1 shows the results in all patients and in selected subgroups.

Figure 1: ATHOS-3: Primary Endpoint – Overall Result and Results in Selected Subgroups

NE Equiv = norepinephrine equivalent dose: the sum of all vasopressor doses with each vasopressor dose converted to the clinically equivalent norepinephrine dose.

Note: The figure above presents effects in various subgroups, all of which are baseline characteristics. The 95% confidence limits that are shown do not take into account the number of comparisons made and may not reflect the effect of a particular factor after adjustment for all other factors. Apparent homogeneity or heterogeneity among groups should not be over-interpreted.

In the GIAPREZA-treated group, the median time to reach the target MAP endpoint was 5 minutes. The effect on MAP was sustained for at least the first three hours of treatment. The median dose of GIAPREZA was 10 ng/kg/min at 30 minutes. Of the 114 responders at Hour 3, only 2 (1.8%) received more than 80 ng/kg/min.

Patients were not necessarily on maximum doses of other vasopressors at the time of randomization. The effect of GIAPREZA when added to maximum doses of other vasopressors is unknown.

Mortality through Day 28 was 46% on GIAPREZA and 54% on placebo (hazard ratio 0.78; 95% confidence interval 0.57 – 1.07).
We aimed to explore the therapeutic effects of endoscopically assisted surgical approaches for HICH. In this retrospective cohort study, we retrospectively analyzed the treatment status of 118 patients with HICH who underwent surgery for hematoma removal. Among them, 61 patients underwent endoscopically assisted hematoma removal surgery through the frontal lobe approach (frontal lobe group); 57 patients underwent endoscopic hematoma assisted via the temporal lobe approach (temporal lobe group). Treatment effects, cerebral hemodynamic status before and after treatment, postoperative prognosis at one month, and incidence of complications were compared between the 2 groups. We found that the total effective treatment rate in the frontal lobe group was higher than that in the temporal lobe group (P < .05). After surgery, the R during the contraction period of the common cerebral artery in both groups decreased compared to that before surgery, and the frontal lobe group was significantly lower than the temporal lobe group; the V and Q were higher than those before surgery, and the frontal lobe group was significantly higher than the temporal lobe group (P < .05). The prognosis of the frontal lobe group was better than that of the temporal lobe group (P < .05). Compared to the endoscopic-assisted temporal approach, the endoscopic-assisted frontal lobe approach for the treatment of HICH can improve cerebral hemodynamic status, enhance treatment efficacy, and improve prognosis.
This study will conduct an efficacy trial of peer mentoring for a high-risk, predominantly minority population of 9- to 15-year-old youths whose parents are HIV infected. The study will also determine mechanisms (mediating variables) through which peer mentoring improves outcomes for the mentees, for example, consistency and continuity of relationship, teaching/role modeling, emotional support/empathy, advocacy, and behavioral reinforcement. After the conclusion of the efficacy trial, the study will continue through naturalistic longitudinal research for an additional 2 years in order to examine the long-term outcomes of peer mentoring.

Participants are randomized to either the peer mentoring program or a control condition (a recreation program). Surveys are conducted at entry into the study, at 6 months, 1 year, and then annually for 2 years. Youths will also participate in focus groups. The surveys and focus groups will assess the youths' psychological functioning, academic adjustment, alcohol and drug use, HIV risk behaviors, delinquent/violent behaviors, peer relationships, prosocial activities, and coping/problem-solving skills. The study will also evaluate family outcomes, including parent/guardian functioning and improved permanency planning.
The role of neoadjuvant treatment in pancreatic adenocarcinoma is still under debate due to a relative lack of robust data compared with other gastrointestinal cancers. According to 2020 NCCN guidelines, neoadjuvant is now the accepted approach for borderline resectable (BR) disease, while upfront surgery is still the recommendation for resectable disease except in cases with high risk features. Another important advantage of treatment with neoadjuvant treatment is an increase in the proportion of patients who receive chemotherapy. Traditionally, only patients with a good performance status and a good recovery after surgery are treated with adjuvant chemotherapy. About 45% of patients do not receive adjuvant chemotherapy after resection due to poor performance status, postoperative morbidity, or early progression of disease. A small cohort study using total neoadjuvant FOLFIRINOX for borderline resectable pancreatic cancer yielded a promising result but the tolerability of FOLFIRINOX limited the use of this regimen in Asian population. In previous T1211 clinical trial, the SLOG regimen showed comparable efficacy with a better safety profile in metastatic pancreatic cancer. This phase II trial will evaluate the feasibility of SLOG regimen in patients with localized pancreatic cancer.
PURPOSE:To obtain the titled plaster having remarkably improved transcutaneous absorption of the active component, by forming an acrylic sticking layer containing indomethacin and polyoxyethylene alkyl (phenyl) ether on a substrate. CONSTITUTION:An acrylic pressure-sensitive adhesive, preferably a copolymer of an alkyl acrylate having a >=4C alkyl and a functional monomer having carboxyl or hydroxyl group in the molecule and/or vinyl acetate, is mixed with indomethacin and an auxiliary selected from polyoxyethylene alkyl ethers and polyoxyethylene alkylphenyl ethers, and the layer of said pressure-sensitive adhesive is applied to the surface of a substrate. The amount of indomethacin is 5-250mg per 1g of the polymer, and that of the auxiliary is 1-35pts.wt. per 100pts.wt of the polymer. The auxiliary is preferably liquid or pasty at 25 deg.C. The active component can be absorbed deep into the skin or in the blood.
Dietary treatment - 3 individual sessions and 3 group sessions. All sessions with a registered dietitian.
PROBLEM TO BE SOLVED: To obtain a new polyamino acid derivative having such a structure that a plurality of amino acids are mutually bound via the amino group's nitrogen atom through crosslinking group, and useful in various applications such as dispersants, metal ion chelating agents and rustproofing agents. SOLUTION: This new polyamino acid derivative is such one that four or more amino acids are mutually bound via the amino group's nitrogen atom through crosslinking group; wherein the crosslinking group is pref. hydroxyl group and/or an alkylene group optionally having ether linkage in the carbon chain [e.g. a group of formula I ((k) is an integer of 1-10)], and this derivative is pref. a derivative of formula II (B is an amino acid side chain; M is H or a counterion; (n) is an integer of >=4). The new polyamino acid derivative is obtained by reaction between (x) mol of epichlorohydrin and/or (y) mol of a polyepoxy compound having (z) epoxy functional groups and an amino acid at [2/3×(x+y×z/2) to 4/3×(x+y×z/2) mol.
Benign prostatic hyperplasia, a prevalent condition in aging men, is characterized by the proliferation of prostatic epithelial and stromal cells, which leads to bladder outlet obstruction and the exacerbation of lower urinary tract symptoms. There is increasing evidence that chronic prostatic inflammation contributes to the pathogenesis and progression of benign prostatic hyperplasia. This review explores the complex relationship between chronic inflammation and benign prostatic hyperplasia, focusing on the underlying mechanisms, clinical implications, and current therapeutic approaches. The pathophysiology of benign prostatic hyperplasia is multifaceted, involving factors such as hormonal changes, hypoxia, urine reflux into prostatic ducts and stroma, autoimmune responses, and infection-induced inflammation. Inflammatory cytokines, particularly interleukin-17 and interleukin-8, may play key roles in tissue remodeling and smooth muscle contraction within the prostate, thereby influencing benign prostatic hyperplasia progression. Current therapies for benign prostatic hyperplasia include α1-blockers, phosphodiesterase 5 inhibitors, 5α-reductase inhibitors, and plant-based treatments (e.g., pollen extract). These therapies aim to alleviate symptoms by reducing prostatic inflammation, improving blood flow, and inhibiting hormonal pathways involved in prostatic enlargement. However, patients with chronic prostatic inflammation often experience more severe lower urinary tract symptoms and may be resistant to conventional treatments. This resistance has prompted the exploration of alternative therapies targeting inflammation. Chronic prostatic inflammation plays a central role in the pathogenesis and severity of benign prostatic hyperplasia. An understanding of its mechanisms will enable the development of more effective treatments to improve the quality of life among patients with benign prostatic hyperplasia.
Patients will receive a 2-hour infusion of 3-AP once in week 1. Beginning in week 2, they will receive 3-AP by mouth twice a day 3 days a week for 3 weeks. Treatment with 3-AP by mouth may repeat every 4 weeks for as long as benefit is shown.
BACKGROUND: Hypoparathyroidism is the most common complication for patients who undergo total thyroidectomy (TT) with bilateral central lymph node dissection (BCLND). The objective of this retrospective study was to investigate the relationship between parathyroid autotransplantation (PA) and postoperative hypoparathyroidism.
MATERIALS AND METHODS: Four hundred and sixty-five patients with papillary thyroid carcinoma (PTC) who underwent TT with BCLND (including prophylactic and therapeutic BCLND) by the same surgeon were enrolled in this retrospective study. They were divided into five groups based on the number of PAs. Group 0 was defined as no PA, while Group 1, 2, 3, and 4 were considered as 1, 2, 3, and 4 PAs during TT with BCLND, respectively.
RESULTS: Transient and permanent hypoparathyroidism occurred in 83 (17.8%) and 2 (0.4%) patients who underwent TT and BCLND, respectively. The incidence of transient hypoparathyroidism increased gradually with an increase in the number of PAs. Compared with the previous group, Groups 2 and 3 had significantly more cases of transient hypoparathyroidism (p=0.03 and p=0.04, respectively). All cases of permanent hypoparathyroidism occurred in the patients without PA. Compared with Group 0, there were more removed central lymph nodes (RCLNs) in patients with one PA. Furthermore, Group 2 had more metastatic central lymph nodes(MCLNs) and RCLNs than Group 1.The number of PAs was the only identified risk factor for transient hypoparathyroidism after the multivariate logistic regression analysis. The median parathyroid hormone level recovered to the normal range within 1 month after surgery.
CONCLUSION: With an increasing number of PAs, the possibility of transient hypoparathyroidism also increases in patients with PTC who undergo TT and BCLND. Considering the rapid recovery of transient hypoparathyroidism in 1 month, two PAs during TT and BCLND could be a good choice, leading to an increase in the central lymph node yield and no permanent hypoparathyroidism. However, this conclusion should be validated in future multicenter prospective studies.
The safety and effectiveness of TRINTELLIX have not been established in pediatric patients.

The safety and efficacy of TRINTELLIX were evaluated in two randomized, double-blind, placebo- and active-controlled 8-week studies in pediatric patients with MDD, one in patients 7 to 11 years of age (N=540 randomized) and one in patients 12 to 17 years of age (N=616 randomized). The primary efficacy endpoint for both studies was the change from baseline to week 8 in the Children's Depression Rating Scale-Revised (CDRS-R) total score. The CDRS-R assesses the severity of depression and change in depressive symptoms in children and adolescents with depression. TRINTELLIX was not superior to placebo in either study. Patients from the controlled 8-week studies were eligible to enroll in a 6-month open-label extension study (N=662 treated). Across the three studies, the most commonly observed adverse reactions to TRINTELLIX in pediatric patients 7 to 17 years of age were generally similar to those observed in adults [see Adverse Reactions (6)].

Antidepressants, such as TRINTELLIX, increase the risk of suicidal thoughts and behaviors in pediatric patients [see Boxed Warning and Warnings and Precautions (5.1)].

Juvenile Animal Toxicity Data

Administration of vortioxetine to juvenile rats (oral doses of 10, 20, and 40 mg/kg/day twice daily from Postnatal Day 21 to 91) resulted in a neurobehavioral effect at the highest dose of 40 mg/kg twice daily (increased peak auditory startle amplitude) during the treatment period. The effect was not seen at the end of the recovery period. When animals were mated after the 4-week recovery period, viability was decreased in the offspring of mated pairs treated with 40 mg/kg twice daily. The no-observed adverse effect dose was 20 mg/kg twice daily based on both the neurobehavioral and reproductive effects. This dose was associated with plasma vortioxetine exposure (AUC) approximately 2 times that in pediatric patients.
Chronic kidney disease is a leading public health problem worldwide. The global prevalence of chronic kidney disease is nearly five hundred million people, with almost one million deaths worldwide. Estimated glomerular filtration rate, imaging such as conventional ultrasound, and histopathological findings are necessary as each technique provides specific information which, when taken together, may help to detect and arrest the development of chronic kidney disease, besides managing its adverse outcomes. However, estimated glomerular filtration rate measurements are hampered by substantial error margins while conventional ultrasound involves subjective assessment. Although histopathological assessment is the best tool for evaluating the severity of the renal pathology, it may lead to renal insufficiency and haemorrhage if complications occurred. Ultrasound shear wave elastography, an emerging imaging that quantifies tissue stiffness non-invasively has gained interest recently. This method applies acoustic force pulses to generate shear wave within the tissue that propagate perpendicular to the main ultrasound beam. By measuring the speed of shear wave propagation, the tissue stiffness is estimated. This paper reviews the literature and presents our combined experience and knowledge in renal shear wave elastography research. It discusses and highlights the confounding factors on shear wave elastography, current and future possibilities in ultrasound renal imaging and is not limited to new sophisticated techniques.
The invention provides avian influenza virus, an inactivated vaccine and a method for preparing the same and belongs to the bioengineering field. H9N2 avian influenza virus HN03 strain is short for avian influenza virus A/chicken/He Nan/03/2009/ (H9N2) strain CGMCCNO: 6258. An H9N2 avian influenza virus inactivated vaccine comprises the H9N2 avian influenza virus HN03 strain using beta-propionolactone inactivation. The method for preparing the vaccine includes preparing H9N2 avian influenza virus HN03 strain venom, performing inactivation and preparing the strain venom into oil emulsion. The H9N2 avian influenza virus HN03 strain is high in immunogenicity and good in cross protection. The antibody valence is high after the H9N2 avian influenza virus inactivated vaccine is vaccinated. The method for preparing the H9N2 avian influenza virus inactivated vaccine is simple and safe, and the cost is low.
Participants across the Philadelphia, PA region were invited to participate in free eye screenings at primary care physician offices or health centers. Screenings included images of optic nerve and macula using non-contact, autofocus, hand-held fundus cameras (Volk Optical, Mentor, Ohio, USA) and measuring Intraocular Pressure (IOP) in millimeters of mercury (mm Hg) with non-contact rebound tonometers TA01I (ICare, Helsinki, Finland).
A method of forming a cross-linked protein structures includes preparing a solution of protein dissolved in a benign solvent and forming an intermediate protein structure from the solution. The intermediate protein structure can be cross-linked by providing for a specific ratio of chemical cross-linking agents to form the cross-linked protein structure. The solution can be prepared by adding a cross-linker of N-hydroxysuccinimide (NHS) and 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride (EDC) at a ratio of two-to-one of NHS to EDC to alcohol. PBS buffer (20×) can be added to the solution until the volume ratio of PBS buffer (20×) to alcohol is about one-to-one. About 16 percent by weight of protein can be dissolved in the solution. The solution can be electrospun to form an intermediate protein structure. After a period of time, the protein structure can be cross-linked to form the cross-linked protein structure.
The invention discloses artemisinin compound suppository for treating female genital diseases. The artemisinin compound suppository is prepared by Artemisia apiacea fermented matter, golden cypress, frankincense, myrrh, lightyellow sophora root, borax, fructus cnidii, Poria cocos, pearl and Sanguis draconis in a way that the ratio of the total weight of the components to the total weight of the artemisinin compound suppository is two to one and sesame oil is used for harmonization. The Artemisia apiacea fermented matter is prepared by Artemisia apiacea leaves and white yeast through fermentation, wherein the weight ratio of Artemisia apiacea leaves to white yeast is 10:1. The invention additionally discloses a preparation method for the artemisinin compound suppository. The preparation method is that: after golden cypress, frankincense, myrrh, lightyellow sophora root, borax, fructus cnidii and Poria cocos are extracted to obtain liquid medicine through distillation method or are directly crushed, Artemisia apiacea fermented matter, the directly crushed pearl powder and Sanguis draconis are added, the obtained mixture is evenly mixed and finally sesame oil is added for harmonization. The artemisinin compound suppository has obvious curative effects on cervical erosion, naboth cyst, vaginitis, condyloma acuminatum and the like, can keep a local high-medicine environment for long time to improve the curative effect and has the advantages of less damage, good curative effect, low toxicity and the like.
An adsorption preparation comprising an activated carbon adsorbent and an adsorbate of a water insoluble or substantially water insoluble oxide, hydroxide or salt of a metal or organometallic group is made by adding a water soluble salt of the metal or organometallic group to a violently stirred suspension of activated carbon, precipitating the insoluble adsorbate and separating, washing and drying the adsorption preparation. The adsorbent: adsorbate ratio may be between 1 : 0.1 and 1 : 10. The adsorbate may be formed in situ by reaction of the dissolved compound with a water soluble hydroxide, acid or salt. Water may be added as a precipitant and the liquid in which the carbon is suspended is preferably miscible with water. Specified adsorbates are Al(NO 3 ) 3 , MgSO 4 , CoCl 3 , SnCl 2 , BiOCl 3 , MnCl, AgCl, (C 6 H 5 ) 3 SnCl and (C 6 H 5 ) 3 SnOH. The preparations may be used in paints, rust proofing, fungicides and bactericides.
PROBLEM TO BE SOLVED: To obtain a compsn. for deodorizing and anti-oxidizing which can be compounded in foods, cosmetics and deodorants and exhibits high deodorizing action, anti-oxidizing action and high safety. SOLUTION: This compsn. is an oily compsn. wherein a solid phase contg. a tea extract-dispersed oil and with a water content of at most 30 wt.% and contg. pref. a water-soluble film forming agent, and a polyhydric alcohol is dispersed under finely divided particle condition in an oil phase contg. an oily ingredient and an emulsifying agent compsn. with an HLB of at most 10 or a powder compsn. wherein the oily compsn. is adsorbed or included into a powder base, and the composition is compounded into foods, cosmetics and deodorants. The foods and the cosmetics compounded with the compsn. for deodorizing and anti-oxidizing are hardly deteriorated in their qualities. In addition, when the foods compounded with the compsn. for deodorizing and anti-oxidizing are eaten, foul breath is decreased or disappears.  In addition, a deodorant incorporated with the compsn. for deodorizing and anti-oxidizing makes odors such as odors of tobaccos, foul smells of toilets and odors of shoes decrease or disappear.
In the first multicenter clinical study in 326 patients with anogenital warts, podofilox gel and its vehicle were applied in a double-blind fashion to comparable patient groups. Of the 260 patients with efficacy data, 176 were treated with podofilox gel. Patients applied podofilox gel twice daily for three consecutive days followed by a 4 day “rest” period.

At the end of 4 weeks, 38.4% of the patients had complete clearing of the wart tissue when treated with podofilox gel.

In the second multicenter clinical trial in 108 evaluable patients with anogenital warts, podofilox topical solution was compared with podofilox gel for efficacy. As in the first clinical trial, patients applied podofilox gel twice daily for three consecutive days followed by a four day “rest” period.

Similar clearance rates were observed. At the end of 4 weeks, 25.6% of the patients had complete clearing of the wart tissue when treated with podofilox gel.